Valbiotis: unveils its outlook to 2030

(CercleFinance.com) - Valbiotisa unveiled this evening its new roadmap for the next five years.


"The Company has all the assets to become a leader in natural health supplements thanks to its unrivalled positioning, backed by clinically tested products", emphasizes Sébastien Peltier, Chairman and co-founder of Valbiotis.

With two launches of its Valbiotis Pro range scheduled in France between now and the end of June, the company believes it will be in a position to generate its first significant commercial revenues as early as 2025.

The company is also counting on the launch, in May 2024, of Valbiotis PRO Cholesterol, a product with 'fully confirmed potential, with 943 orders booked in the fourth quarter of 2024, backed by a high rate of restocking in pharmacies (48% in December), as well as a very significant rate of re-purchases via the internet (45%)'.

Valbiotis is talking about a commercial boom that should enable it to post sales of at least 25 ME in 2027, with positive EBITDA.

By 2030, our ambition is to generate sales in excess of 100 ME, taking into account an international contribution of at least 30%", emphasizes Sébastien Peltier.

Copyright (c) 2025 CercleFinance.com. All rights reserved.